Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Descriptor ID |
D000971
|
MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2008 | 1 | 0 | 1 |
2013 | 0 | 2 | 2 |
2016 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy. J Steroid Biochem Mol Biol. 2019 10; 193:105415.
-
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 2018 09; 123:91-98.
-
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer. Int J Mol Sci. 2017 Nov 02; 18(11).
-
Combination treatment with flavonoid morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. Int J Oncol. 2016 Aug; 49(2):487-98.
-
STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014 Feb; 44(2):403-11.
-
Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One. 2013; 8(1):e53287.
-
Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells. Anticancer Res. 2008 Nov-Dec; 28(6A):3579-92.
-
Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma. Int J Clin Oncol. 2007 Feb; 12(1):52-5.
-
Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005 Nov 20; 23(33):8289-95.
-
New approaches to reverse resistance to hormonal therapy in human breast cancer. Drug Resist Updat. 2005 Aug; 8(4):219-33.